Search

everythinglearnresearchcommunity

for

Search:↓

IGF-1 may affect hair growth and loss, but more research is needed to confirm effective and safe treatments.

Thymosin β4 helps improve skin healing and reduce scarring.

The normal human prostate does not significantly affect blood DHT levels.

The document concludes that there is a significant lack of reporting on the sex and age of cells in skin research, which could affect clinical trials and treatments.

Topical vitamin D is useful for some skin conditions but not effective for others, and more research is needed.

Cholesterol balance is important for hair health, and problems with it can lead to hair loss conditions.

The cause of atypical Cushing's syndrome in dogs, possibly linked to sex hormones, is not yet proven.

Amenorrhea, or the absence of periods, should be evaluated by age 15 or within five years of early breast development, and is most commonly caused by conditions like polycystic ovary syndrome and hypothalamic amenorrhea.

The Random Forest algorithm was the most accurate at diagnosing Polycystic Ovarian Syndrome.

Finasteride reduces response to stress and rewards, affecting behavior and mental health.

Some drugs can cause skin and hair color changes, often reversible when the drug is stopped.

Women with mild acne are more likely to have polycystic ovary syndrome (PCOS) than those without acne.

The conclusion is that skin and hair patterns are formed by a mix of cell activities, molecular signals, and environmental factors.

Most treatments for hair loss in 1997 were not effective for most people, and maintaining hair growth was difficult.

Hair loss in postmenopausal woman caused by ovarian issue.

The estradiol valerate/dienogest oral contraceptive helps with heavy periods, may improve acne and symptoms in PCOS, and doesn't affect sexual function.

Prostate-specific antigen may be a new marker for excess male hormones in women with polycystic ovary syndrome.

Estrogen and prolactin may play bigger roles in female hair loss than previously thought.

Both treatments reduced excessive hair growth in PCOS, but there was no difference in weight, hair score, hormone levels, or insulin resistance.

A woman was the first known case to have both polycystic ovary syndrome and autoimmune polyglandular syndrome type 2, suggesting a need to check for both conditions in similar patients.

The document concludes that treating androgen excess needs patience, managing expectations is important, and many drugs used are not officially approved, suggesting cosmetic options for mild cases.

Older women often have vulva issues due to less estrogen, which can be misdiagnosed and lead to wrong treatments.

Blood removal and birth control pills both helped with hormone levels in women with PCOS, but birth control was better for regular periods and blood removal had fewer side effects.

HSD3B1 gene variant and being overweight linked to hair loss in women with polycystic ovary syndrome.

The document concludes that combination therapy is most effective for treating excessive hair growth in women with idiopathic hirsutism, and more research is needed to understand the condition.

Certain drugs, especially antiandrogens and spironolactone, significantly increase the risk of gynecomastia.

Updated treatments for female hair loss include minoxidil, antiandrogens, hair transplants, and light therapy.

Aromatase inhibitors can cause skin issues, especially with anastrozole and exemestane, so monitoring is important.

Excess maternal androgens can cause heart problems in offspring.

The chapter explains the causes of excessive hair growth and masculinization in women and how to measure hormone levels related to these conditions.